Brenda F Kurland
Affiliation: Fred Hutchinson Cancer Research Center
- Accommodation of missing data in supportive and palliative care clinical trialsBrenda F Kurland
Fred Hutchinson Cancer Research Center, Seattle, Washington 98019, USA
Curr Opin Support Palliat Care 6:465-70. 2012..Clinical trials to evaluate the supportive and palliative care treatments have some different missing data concerns than the other clinical trials. This study reviews the literature on missing data as it may apply to these trials...
- Promise and pitfalls of quantitative imaging in oncology clinical trialsBrenda F Kurland
Fred Hutchinson Cancer Research Center, Seattle, WA 98019, USA
Magn Reson Imaging 30:1301-12. 2012..Strategies for overcoming these constraints are presented...
- Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patientsBrenda F Kurland
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA
EJNMMI Res 2:34. 2012..abstract:..
- Longitudinal change in positive affect in community-dwelling older personsBrenda F Kurland
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
J Am Geriatr Soc 54:1846-53. 2006..To determine whether positive affect, defined as emotional contentment and happiness, remains stable in late life and to identify predictors of longitudinal change in positive affect...
- Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PETBrenda F Kurland
Department of Clinical Statistics, Fred Hutchinson Cancer Research Center, Seattle Washington 98109, USA
J Nucl Med 52:1541-9. 2011..We describe within-patient (site-to-site) and between-patient heterogeneity of lesions in patients scheduled to receive endocrine therapy...
- PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptakeLisa K Dunnwald
Division of Nuclear Medicine and Medical Oncology, University of Washington, Seattle, Washington 98109, USA
Clin Cancer Res 17:2400-9. 2011..Serial dynamic [(18)F]-FDG (fluorodeoxyglucose) PET scans were used to compare kinetic parameters with the standardized uptake value (SUV) as predictors of pathologic response, disease-free survival (DFS), and overall survival (OS)...
- Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancerSavannah C Partridge
Department of Radiology, University of Washington School of Medicine, Seattle, Washington 98109 1023, USA
J Magn Reson Imaging 32:1124-31. 2010....
- Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancerLisa K Dunnwald
Department of Bioengineering, Division of Nuclear Medicine, University of Washington, Seattle, WA, USA
J Clin Oncol 26:4449-57. 2008..Serial positron emission tomography (PET) has been shown to predict pathologic response in this setting. We evaluated serial quantitative PET tumor blood flow (BF) and metabolism as in vivo measurements to predict patient outcome...
- Multicenter trials using ¹⁸F-fluorodeoxyglucose (FDG) PET to predict chemotherapy response: effects of differential measurement error and bias on power calculations for unselected and enrichment designsBrenda F Kurland
aFred Hutchinson Cancer Research Center, Seattle, WA, USA
Clin Trials 10:886-95. 2013..However, it is often unknown how measurement error and bias in a multicenter trial will differ from that in single-institution studies...
- Quantitative diffusion-weighted imaging as an adjunct to conventional breast MRI for improved positive predictive valueSavannah C Partridge
Department of Radiology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA 98109 1023, USA
AJR Am J Roentgenol 193:1716-22. 2009..The purpose of our study was to investigate whether adding diffusion-weighted imaging (DWI) to dynamic contrast-enhanced MRI (DCE-MRI) could improve the positive predictive value (PPV) of breast MRI...
- Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancerHannah M Linden
Department of Medicine, University of Washington, Seattle, Washington, USA
Clin Cancer Res 17:4799-805. 2011..To determine, by molecular imaging, how in vivo pharmacodynamics of estrogen-estrogen receptor (ER) binding differ between types of standard endocrine therapy...
- Apparent diffusion coefficient values for discriminating benign and malignant breast MRI lesions: effects of lesion type and sizeSavannah C Partridge
Department of Radiology, University of Washington School of Medicine, Seattle Cancer Care Alliance, Seattle, WA 98109 1023, USA
AJR Am J Roentgenol 194:1664-73. 2010..The purpose of this study was to determine whether lesion type and size affect discrimination of benign and malignant breast lesions with diffusion-weighted MRI...
- Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)Jennifer M Specht
Division of Medical Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, 825 Eastlake Avenue E, G3 200, Seattle, WA 98109, USA
Breast Cancer Res Treat 105:87-94. 2007..Our goal was to evaluate the prognostic power of serial FDG PET in BD breast cancer patients undergoing treatment...
- Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancerJennifer M Specht
Medical Oncology and Nuclear Medicine, Department of Medicine, University of Washington, Seattle, Washington 98109, USA
Clin Cancer Res 16:2803-10. 2010..This analysis examines tumor metabolism and perfusion by tumor subtype...
- Quantitative assessment of dynamic PET imaging data in cancer imagingMark Muzi
Department of Radiology, University of Washington, Seattle, WA 98195 6004, USA
Magn Reson Imaging 30:1203-15. 2012....
- Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and (15)O-water positron emission tomography blood flow in breast cancerPeter R Eby
Department of Radiology, University of Washington, Seattle Cancer Care Alliance, 825 Eastlake Avenue East, G3 200, Seattle, WA 98109 1023, USA
Acad Radiol 15:1246-54. 2008....
- Probability of malignancy for lesions detected on breast MRI: a predictive model incorporating BI-RADS imaging features and patient characteristicsWendy B Demartini
Department of Radiology, University of Washington Medical Center, 1959 NE Pacific, Seattle, WA 98195, USA
Eur Radiol 21:1609-17. 2011..To predict the probability of malignancy for MRI-detected breast lesions with a multivariate model incorporating patient and lesion characteristics...
- Preoperative and intraoperative sonographic visibility of collagen-based breast biopsy marker clipsPeter R Eby
Department of Radiology, University of Washington Medical Center, Seattle, WA, USA
Acad Radiol 17:340-7. 2010..The aim of this study was to determine the sonographic visibility of implanted collagen-based breast biopsy marker clips in the clinic and operating room...
- Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSFRobert K Doot
Department of Bioengineering, University of Washington, Seattle, Washington, USA
J Nucl Med 48:920-5. 2007..We tested whether chemotherapy and treatment with granulocyte colony-stimulating factor (CSF) changed the blood clearance curves and therefore affected the relationship between MRFDG and SUV...
- Assessment of joint and fascia manifestations in chronic graft-versus-host diseaseYoshihiro Inamoto
Fred Hutchinson Cancer Research Center, Seattle, Washington
Arthritis Rheumatol 66:1044-52. 2014....
- Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancerLanell M Peterson
Department of Radiology, University of Washington Medical Center, Seattle, WA 98195, USA
Nucl Med Biol 38:969-78. 2011..Assessment of factors that could affect the quantitative level of FES uptake is important as part of the validation of FES PET for evaluating regional ER expression in breast cancer...
- Design considerations for using PET as a response measure in single site and multicenter clinical trialsRobert K Doot
Department of Radiology, University of Washington, Seattle, 98109 1023, USA
Acad Radiol 19:184-90. 2012..Here we demonstrate impacts of PET measurement error and choice of quantification method on clinical trial design...
- BI-RADS lesion characteristics predict likelihood of malignancy in breast MRI for masses but not for nonmasslike enhancementRobert L Gutierrez
Department of Radiology, University of Washington Medical Center, University of Washington, Seattle, WA
AJR Am J Roentgenol 193:994-1000. 2009..The purpose of our study was to evaluate the predictive features of BI-RADS lesion characteristics and the risk of malignancy for mammographically and clinically occult lesions detected initially on breast MRI...
- Differential diagnosis of mammographically and clinically occult breast lesions on diffusion-weighted MRISavannah C Partridge
Department of Radiology, University of Washington, Seattle Cancer Care Alliance, Seattle, Washington 98109 1023, USA
J Magn Reson Imaging 31:562-70. 2010..To investigate the diagnostic performance of diffusion-weighted imaging (DWI) for mammographically and clinically occult breast lesions...
- A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC)Lanell M Peterson
Radiology Nuclear Medicine, University of Washington Medical Center Seattle Cancer Care Alliance, Seattle, WA, USA
Mol Imaging Biol 16:431-40. 2014..16α-[(18)F]-fluoro-17β-estradiol positron emission tomography (FES-PET) quantifies estrogen receptor (ER) expression in tumors and may provide diagnostic benefit...
- Internal mammary nodal chain drainage is a prognostic indicator in axillary node-positive breast cancerMichelle S Yao
Department of Radiation Oncology, University of Washington Medical School, Seattle, WA, USA
Ann Surg Oncol 14:2985-93. 2007..Internal mammary (IM) nodes are a potential site of breast lymphatic drainage. We examined the relationship between lymphoscintigraphic evidence of IM drainage and survival in early-stage breast cancer patients (pts)...
- Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trialRenato G Martins
University of Washington, Seattle Cancer Care Alliance, 825 Eastlake Ave E MS G4 940, Seattle, WA 98109, USA
J Clin Oncol 31:1415-21. 2013..Erlotinib is a small-molecule inhibitor of EGFR. Adding EGFR inhibition to standard cisplatin-radiotherapy may improve efficacy...
- Salvage lung resection after definitive radiation (>59 Gy) for non-small cell lung cancer: surgical and oncologic outcomesJulie E Bauman
Department of Medical Oncology, University of Washington, Seattle, Washington, USA
Ann Thorac Surg 86:1632-8; discussion 1638-9. 2008..Although originally considered inoperable, select patients are referred for surgical salvage. We describe a series of salvage lung resection after curative-intent radiation...
- Directly parameterized regression conditioning on being alive: analysis of longitudinal data truncated by deathsBrenda F Kurland
National Alzheimer s Coordinating Center, University of Washington, 4311 11th Avenue NE 300, Seattle, WA 98105, USA
Biostatistics 6:241-58. 2005..Simulation studies and an analysis of monthly disability status illustrate potential bias in regression methods that do not explicitly condition on survival...
- Prospective neurocognitive function over 5 years after allogeneic hematopoietic cell transplantation for cancer survivors compared with matched controls at 5 yearsKaren L Syrjala
Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109 1024, USA
J Clin Oncol 29:2397-404. 2011..This study prospectively examined the trajectory and extent of long-term cognitive dysfunction, with a focus on 1 to 5 years after treatment...
- A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumorsXiaoyu Qu
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
PLoS ONE 8:e74671. 2013..64, P<0.001). Overall, the three-marker FISH panel may represent a useful tool for risk stratification of prostate cancer patients. ..
- Validation of measurement scales in ocular graft-versus-host diseaseYoshihiro Inamoto
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
Ophthalmology 119:487-93. 2012..Candidate scales were recommended for use in clinical trials by the National Institutes of Health (NIH) Chronic GVHD Consensus Conference or have been previously validated in dry eye syndromes...
- Clinical indication and patient age predict likelihood of malignancy in suspicious breast MRI lesionsRobert L Gutierrez
Department of Radiology, University of Washington Medical Center, University of Washington, Seattle, WA, USA
Acad Radiol 16:1281-5. 2009..To evaluate the associations of patient age and clinical indication with the risk of malignancy for suspicious lesions initially detected on breast magnetic resonance imaging (MRI)...
- External beam radiation therapy and abiraterone in men with localized prostate cancer: safety and effect on tissue androgensEunpi Cho
University of Washington School of Medicine, Seattle, Washington Fred Hutchinson Cancer Research Center, Seattle, Washington
Int J Radiat Oncol Biol Phys 92:236-43. 2015..Addition of abiraterone to luteinizing hormone-releasing hormone agonist (LHRHa) with radiation has not been reported. We examined the safety of this combination as well as its impact on androgen suppression...
- Sexual function changes during the 5 years after high-dose treatment and hematopoietic cell transplantation for malignancy, with case-matched controls at 5 yearsKaren L Syrjala
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Blood 111:989-96. 2008..05) reported problems. Thus, despite some recovery, sexual dysfunction remained a major problem for men and women after HCT. Aggressive efforts are needed to treat these deficits...
- Marginalized transition models for longitudinal binary data with ignorable and non-ignorable drop-outBrenda F Kurland
National Alzheimer s Coordinating Center, University of Washington, Department of Epidemiology, 4311 11th Ave NE 300, Seattle, WA 98105, USA
Stat Med 23:2673-95. 2004..MTM and IPCW-GEE regression parameters both display misspecification bias for MAR and non-ignorable missing data, and both reduce bias noticeably by improving model fit...
- Prognostic effect of prior disability episodes among nondisabled community-living older personsThomas M Gill
Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06504, USA
Am J Epidemiol 158:1090-6. 2003..More frequent assessments of functional status may be warranted in epidemiologic studies and clinical trials when disability is a primary focus...
- A 3-dimensional analysis of molar movement during headgear treatmentJennifer L Ashmore
Department of Orthodontics, University of Washington, Seattle 98195 7446, USA
Am J Orthod Dentofacial Orthop 121:18-29; discussion 29-30. 2002..Several reasons could account for the wide range of individual variation and warrant exploration...